Item 7.01. Regulation FD Disclosure.

On November 30, 2020, Moderna, Inc. (the "Company") issued a press release announcing the primary efficacy analysis for its vaccine candidate against COVID-19, mRNA-1273, and that the Company expects to file for Emergency Use Authorization for mRNA-1273 with the U.S. Food and Drug Administration on November 30, 2020. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Moderna, Inc. on November 30, 2020

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses